Caitlin Burke1, Matthew R Dreher2, Ayele H Negussie3, Andrew S Mikhail3, Pavel Yarmolenko4, Aakash Patel4,5, Brenden Skilskyj5, Bradford J Wood3, Dieter Haemmerich6. 1. a Department of Bioengineering , George Mason University , Fairfax , VA , USA. 2. b BTG International Inc , West Conshohocken , PA , USA. 3. c Center for Interventional Oncology, Radiology and Imaging Sciences , Clinical Center, National Institutes of Health , Bethesda , MD , USA. 4. d Sheikh Zayed Institute, Children's National , Washington , DC , USA. 5. e Department of Bioengineering , University of Maryland , College Park , MD , USA. 6. f Department of Pediatrics , Medical University of South Carolina , Charleston , SC , USA.
Abstract
PURPOSE: Current release assays have inadequate temporal resolution ( ∼ 10 s) to characterise temperature sensitive liposomes (TSL) designed for intravascular triggered drug release, where release within the first few seconds is relevant for drug delivery. MATERIALS AND METHODS: We developed a novel release assay based on a millifluidic device. A 500 µm capillary tube was heated by a temperature-controlled Peltier element. A TSL solution encapsulating a fluorescent compound was pumped through the tube, producing a fluorescence gradient along the tube due to TSL release. Release kinetics were measured by analysing fluorescence images of the tube. We measured three TSL formulations: traditional TSL (DPPC:DSPC:DSPE-PEF2000,80:15:5), MSPC-LTSL (DPPC:MSPC:DSPE-PEG2000,85:10:5) and MPPC-LTSL (DPPC:MMPC:PEF2000,86:10:4). TSL were loaded with either carboxyfluorescein (CF), Calcein, tetramethylrhodamine (TMR) or doxorubicin (Dox). TSL were diluted in one of the four buffers: phosphate buffered saline (PBS), 10% bovine serum albumin (BSA) solution, foetal bovine serum (FBS) or human plasma. Release was measured between 37-45 °C. RESULTS: The millifluidic device allowed measurement of release kinetics within the first few seconds at ∼5 ms temporal resolution. Dox had the fastest release and highest release %, followed by CF, Calcein and TMR. Of the four buffers, release was fastest in human plasma, followed by FBS, BSA and PBS. CONCLUSIONS: The millifluidic device allows measurement of TSL release at unprecedented temporal resolution, thus allowing adequate characterisation of TSL release at time scales relevant for intravascular triggered drug release. The type of buffer and encapsulated compound significantly affect release kinetics and need to be considered when designing and evaluating novel TSL-drug combinations.
PURPOSE: Current release assays have inadequate temporal resolution ( ∼ 10 s) to characterise temperature sensitive liposomes (TSL) designed for intravascular triggered drug release, where release within the first few seconds is relevant for drug delivery. MATERIALS AND METHODS: We developed a novel release assay based on a millifluidic device. A 500 µm capillary tube was heated by a temperature-controlled Peltier element. A TSL solution encapsulating a fluorescent compound was pumped through the tube, producing a fluorescence gradient along the tube due to TSL release. Release kinetics were measured by analysing fluorescence images of the tube. We measured three TSL formulations: traditional TSL (DPPC:DSPC:DSPE-PEF2000,80:15:5), MSPC-LTSL (DPPC:MSPC:DSPE-PEG2000,85:10:5) and MPPC-LTSL (DPPC:MMPC:PEF2000,86:10:4). TSL were loaded with either carboxyfluorescein (CF), Calcein, tetramethylrhodamine (TMR) or doxorubicin (Dox). TSL were diluted in one of the four buffers: phosphate buffered saline (PBS), 10% bovineserum albumin (BSA) solution, foetal bovine serum (FBS) or human plasma. Release was measured between 37-45 °C. RESULTS: The millifluidic device allowed measurement of release kinetics within the first few seconds at ∼5 ms temporal resolution. Dox had the fastest release and highest release %, followed by CF, Calcein and TMR. Of the four buffers, release was fastest in human plasma, followed by FBS, BSA and PBS. CONCLUSIONS: The millifluidic device allows measurement of TSL release at unprecedented temporal resolution, thus allowing adequate characterisation of TSL release at time scales relevant for intravascular triggered drug release. The type of buffer and encapsulated compound significantly affect release kinetics and need to be considered when designing and evaluating novel TSL-drug combinations.
Entities:
Keywords:
TSL; Temperature sensitive liposomes; drug delivery; hyperthermia; nanoparticles; thermosensitive liposomes
Authors: G Kong; G Anyarambhatla; W P Petros; R D Braun; O M Colvin; D Needham; M W Dewhirst Journal: Cancer Res Date: 2000-12-15 Impact factor: 12.701
Authors: Lars H Lindner; Martin Hossann; Michael Vogeser; Nicole Teichert; Kirsten Wachholz; Hansjoerg Eibl; Wolfgang Hiddemann; Rolf D Issels Journal: J Control Release Date: 2007-10-22 Impact factor: 9.776
Authors: Lars H Lindner; Martin E Eichhorn; Hansjoerg Eibl; Nicole Teichert; Marcus Schmitt-Sody; Rolf D Issels; Marc Dellian Journal: Clin Cancer Res Date: 2004-03-15 Impact factor: 12.531
Authors: Amy Lee Bredlau; Anjan Motamarry; Chao Chen; M A McCrackin; Kris Helke; Kent E Armeson; Katrina Bynum; Ann-Marie Broome; Dieter Haemmerich Journal: Drug Deliv Date: 2018-11 Impact factor: 6.419
Authors: Krishna K Ramajayam; A Marissa Wolfe; Anjan Motamarry; Georges J Nahhas; John Yost; Michael J Yost; Dieter Haemmerich Journal: IEEE Open J Eng Med Biol Date: 2021-05-11